Navigation Links
Beaumont Hospital, Royal Oak Treats Its First Patients With Elekta Axesse
Date:10/30/2007

New robotic, image-guided stereotactic radiation system treats cancer patients quickly and effectively with highly accurate tumor targeting

ROYAL OAK, Mich., Oct. 30 /PRNewswire/ -- Beaumont Hospital, Royal Oak (Royal Oak, Michigan, USA) has performed its first treatments using the new Elekta Axesse(TM), the ultimate whole-body cancer treatment system. Elekta Axesse sets new standards for precision and therapeutic efficacy in stereotactic radiation therapy, which involves three-dimensional CT imaging for tumor targeting accuracy.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020318/ELEKTALOGO )

Since 2006, Beaumont Hospital has been running a successful intracranial radiosurgery program with Leksell Gamma Knife, and the hospital now is expanding its stereotactic treatment offerings to all parts of the anatomy.

"We chose Elekta Axesse because of its versatility," says Alvaro Martinez, M.D., F.A.C.R., corporate chairman, Radiation Oncology, Beaumont Hospitals. "We now can stereotactically treat both intra- and extra-cranial lesions, and the 6D robotically-controlled tabletop gives us the freedom to position the patient at virtually any angle. This enables a much more accurate and precise treatment for these lesions than we could provide in the past."

Integrating advanced technology and software to elevate the patient experience, streamline clinician workflow

The advanced 3D imaging capabilities of Elekta Axesse facilitate rapid, precise targeting of tumors, and the highly-conformal radiation delivery system effectively treats tumors while minimizing damage to patients' healthy tissue.

"Elekta Axesse enables us to attain sub-millimeter accuracy by planning in 3D and imaging patients in 3D prior to treatment, every day," says Dr. Martinez.

Elekta Axesse also integrates non-invasive patient immobilization to ensure patients properly
'/>"/>

SOURCE Elekta, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The Genesis of Gendicine: The Story Behind the First Gene Therapy
2. Midwest life science stocks sizzle in a tepid first quarter
3. Morgridge Institute for Research seeks first CEO
4. Sonic Foundry reports first cash-positive quarter
5. Angel investors commit $12.7B in first half of `06
6. Aurora team implants Wisconsins first total artificial heart
7. First half of 2006 roundup: Big Pharma trumps biotech
8. GE announces first installation of Discovery VCT
9. GE Healthcare enjoys robust growth in first quarter
10. Madison asks for wireless bids; airport, downtown would be first
11. Tech Digest: Inacom, PKWare at Infosecurity, Firstlogic, Teklynx
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... ANGELES , May 21, 2015  CytRx ... and development company specializing in oncology, today announced ... clinical trial with aldoxorubicin for the treatment of ... brain cancer.  The open-label, multisite trial is designed ... aldoxorubicin in patients whose tumors have progressed following ...
(Date:5/21/2015)... VANCOUVER , May 21, 2015 /PRNewswire/ - ... a clinical stage regenerative medicine company focused on ... an upcoming poster presentation at the International Society ... treatment for chronic Achilles tendinosis currently in a ... on May 29 th from 5:30 PM ...
(Date:5/20/2015)... SAN FRANCISCO, Calif. , May 20, 2015 ... VCYT ) today presented preliminary data demonstrating the ... distinguish idiopathic pulmonary fibrosis (IPF) from other interstitial ... The findings suggest the classifier,s potential to help ... surgery to resolve ambiguity in IPF diagnosis – ...
(Date:5/20/2015)... , May 19, 2015 Research and Markets ... of the "Global Cell Therapy Market Outlook 2020 ... of cell therapy in tissue and regenerative medicine is ... no other options which could help in the growth ... this segment but they are unable to form new ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
... stimulate economy ALEXANDRIA, Va., May 7 Today, the ... proposing level funding for the Carl D. Perkins Career ... The Perkins Act is the primary source of federal ... and real-world careers. The Association for Career and Technical ...
... Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), ... development of novel antibiotics for the treatment of ... presenting two presentations and two posters at the ... Diseases (ECCMID) taking place in Helsinki, Finland from ...
... -- Delcath Systems, Inc., (Nasdaq: DCTH ) ... Hepatic Perfusion (PHP(TM)) System for the treatment of cancers of ... of the Atlantic Melanoma Center and a Principal Investigator of ... Congress on Melanoma, to be held in Vienna, Austria, May ...
Cached Biology Technology:Obama Budget Level Funds Career Technical Education 2Obama Budget Level Funds Career Technical Education 3Rib-X Pharmaceuticals Announces Presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2Rib-X Pharmaceuticals Announces Presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 3Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma 2Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma 3
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated (NASDAQ: ... interface solutions, today announced the appointment of ... Chief Financial Officer, reporting to Rick Bergman ... current Chief Financial Officer, Kathleen Bayless , ... Mr. Ali brings extensive financial management ...
(Date:5/10/2015)... May 11, 2015 Fingerprint Cards (FPC) ... and FPC1155 from the distributor World Peace Industrial Group (WPI), ... in Asia . Deliveries are planned to ... used by smartphone manufacturers in China . ... communicated revenue guidance of + 1 000 MSEK for 2015.   ...
(Date:5/6/2015)... 6, 2015 LifeBEAM, a developer of bio-sensing ... announced today that they will expand their partnership in ... bio-sensing cycling helmet and the first joint project between ... colors in order to give cyclists more style choices ... LifeBEAM and Lazer announced their plan to release a ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... /PRNewswire-iReach/ -- Picofemto LLC , a biomedical software company ... the deployment of its first product, EEG Decision Support ... Cliniscan TM . (Photo: ... , the innovative web-based software as a service (SaaS) ...
... the two copies of each chromosomecalled sister chromatidsto ensure ... during cell division. In this way, each daughter cell ... cell. Pds5 is a protein associated with cohesins; ... there are two variants of Pds5, Pds5A and Pds5B, ...
... , Oct. 2, 2013 SOFIE BIOSCIENCES, an emerging ... Tomography (PET) probes, scanners and chemistry systems, announced today ... company a grant under the Small Business Innovation Research ... over three years, will be administered by the National ...
Cached Biology News:Picofemto Deploys Cloud-Based Cliniscan EEG Analytics and Clinical Decision Support 2Picofemto Deploys Cloud-Based Cliniscan EEG Analytics and Clinical Decision Support 3CNIO researchers delve into the behavior of cohesins 2SOFIE BIO Receives $1.8M Phase II SBIR Grant 2
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Rabbit polyclonal to NIRF ( Abpromise for all tested applications). Antigen: Synthetic peptide derived from residues 186-235 of human NIRF. Entrez Gene ID: 115426 Swiss Protein ID: Q96PU...
...
...
Biology Products: